Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,746.50
Bid: 1,742.50
Ask: 1,743.00
Change: 6.50 (0.37%)
Spread: 0.50 (0.029%)
Open: 1,730.00
High: 1,746.50
Low: 1,729.00
Prev. Close: 1,740.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Markets in the red with BoE, Fed in focus

Wed, 20th Nov 2013 11:33

- BoE voted unanimously on policy at last meeting- MPC attempts to play down rate-hike fears- Taper in focus ahead of FOMC minutestechMARK 2,627.20 -0.64%FTSE 100 6,670.70 -0.41%FTSE 250 15,181.39 -0.55%UK markets were trading in the red on Wednesday after the Bank of England expressed concerns with the economic recovery and as investors awaited the minutes of the latest Federal Reserve policy meeting. A number of heavyweight stocks were providing a drag on London's FTSE 100 index by midday after going ex-dividend, meaning that from today investors won't be able to get their hands on the companies' latest payouts.It was revealed this morning that the Bank of England's Monetary Policy Committee (MPC) voted unanimously to maintain the Bank Rate at 0.5% and the stock of asset purchases at £375bn at its latest meeting, as expected. However, the MPC attempted to ease fears over a sooner-than-expected tightening in monetary policy as the minutes of the meeting expressed "uncertainties over the durability of the recovery". The central bank reiterated that rates would be kept low until the unemployment rate reaches the 7% threshold, at which point policymakers would then reassess its stance.Analyst Philip Shaw from Investec said that the minutes didn't provide any firm clues to the timing of a possible rate increase. "Rather they conveyed the degree of uncertainty on the committee on the economic outlook and the recovery in productivity, which will be key factors in the monetary policy debate," he said.Meanwhile, the Federal Open Market Committee (FOMC) will release details of its October meeting later this evening as markets wait to hear about the central bank's decision to maintain its stimulus programme last month.However, comments from Fed Chairman Ben Bernanke last night were in focus this morning after he reiterated that any tapering of asset purchases remains dependent on incoming economic data, as he held back from shedding any light on the timetable for an impending withdrawal.Telecom Plus soars after H1 results, acquisitionsUtilities reseller Telecom Plus was a high riser this morning after agreeing to pay £218m to buy back two gas and electricity supply businesses from Npower which it sold in 2006. The announcement came as the firm delivered a 17% increase in revenues in the first half, as profits rose 10.1%.Ex-div stocks were weighing on the FTSE 100 with Vodafone, Tate & Lyle, Next, Carnival and Sainsbury among the stocks trading without the right to their latest payouts.Drinks group Diageo was under the weather after Chief Executive Ivan Menezes was reported as saying that the "uncertain" macro environment will continue to limit sales growth. Sector peer SABMiller was also out of favour this morning.Airline group easyJet was extending gains made yesterday after the company delivered a 51% increase in annual profits and unveiled an unexpected special dividend to shareholders.GlaxoSmithKline rose after completing the partial sale of Aspen Pharmacare, raising gross proceeds of 7.06bn South African rand ($695m).Engineering and construction firm Kentz was higher after being awarded a $190m contract with Qatar Petroleum for services on 775 wells across the Dukhan Oilfield in Qatar, extending the firms' long-standing relationship which started back in 1997.Fund manager Aberdeen rose after analysts at Bank of America Merrill Lynch upgraded their rating on the stock from 'underperform' to 'neutral'. FTSE 100 - RisersAberdeen Asset Management (ADN) 484.90p +2.04%British Sky Broadcasting Group (BSY) 838.50p +1.64%Travis Perkins (TPK) 1,752.00p +1.57%easyJet (EZJ) 1,362.00p +1.26%Pearson (PSON) 1,342.00p +0.98%Johnson Matthey (JMAT) 3,116.00p +0.84%Aviva (AV.) 429.90p +0.68%Rio Tinto (RIO) 3,277.50p +0.57%William Hill (WMH) 363.10p +0.50%Royal Dutch Shell 'B' (RDSB) 2,200.00p +0.46%FTSE 100 - FallersRexam (REX) 488.50p -2.98%Vodafone Group (VOD) 227.15p -2.11%Amec (AMEC) 1,160.00p -2.03%Hammerson (HMSO) 505.00p -1.94%Persimmon (PSN) 1,163.00p -1.86%Melrose Industries (MRO) 298.20p -1.84%Tate & Lyle (TATE) 806.50p -1.77%Bunzl (BNZL) 1,368.00p -1.72%Sainsbury (J) (SBRY) 404.80p -1.68%Vedanta Resources (VED) 955.00p -1.65%FTSE 250 - RisersTelecom Plus (TEP) 1,745.00p +15.79%International Personal Finance (IPF) 591.50p +2.69%Kentz Corporation Ltd. (KENZ) 555.50p +2.49%Lancashire Holdings Limited (LRE) 811.50p +2.40%BH Global Ltd. USD Shares (BHGU) 11.91 +1.79%Rathbone Brothers (RAT) 1,559.00p +1.56%BH Macro Ltd. EUR Shares (BHME) € 20.00 +1.52%NMC Health (NMC) 375.50p +1.49%BH Macro Ltd. USD Shares (BHMU) 19.69 +1.44%BTG (BTG) 446.30p +1.39%FTSE 250 - FallersTalkTalk Telecom Group (TALK) 266.20p -3.55%Centamin (DI) (CEY) 48.19p -3.43%Spirent Communications (SPT) 102.20p -3.31%Bovis Homes Group (BVS) 744.50p -2.93%African Barrick Gold (ABG) 186.40p -2.76%ITE Group (ITE) 304.10p -2.69%Kenmare Resources (KMR) 20.49p -2.66%Wood Group (John) (WG.) 788.50p -2.41%Ashmore Group (ASHM) 378.70p -2.40%Hiscox Ltd (HSX) 662.00p -2.36%BC
More News
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more
14 Nov 2023 17:04

LONDON MARKET CLOSE: FTSE 100 underwhelms as stocks jump after US CPI

(Alliance News) - European equities jumped in the wake of a cooler-than-expected US inflation reading, which took some sting out of a recent hawkish reassessment of the Federal Reserve interest rate outlook.

Read more
13 Nov 2023 09:47

GSK hails momelotinib opinion from European Medicines Agency committee

(Alliance News) - GSK PLC on Monday announced that a European Medicines Agency panel has given a positive opinion recommending momelotinib to treat myelofibrosis patients with anaemia.

Read more
9 Nov 2023 15:50

UK dividends calendar - next 7 days

Friday 10 November 
Bodycote PLCdividend payment date
Breedon Group PLCdividend payment date
Chesnara PLCdividend payment date
Finsbury Growth & Income Trust PLCdividend payment date
Invesco Bond Income Plus Ltddividend payment date
JPMorgan Emerging Markets Investment Trust PLCdividend payment date
Kerry Group PLCdividend payment date
Merchants Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCspecial dividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Senior PLCdividend payment date
Spectris PLCdividend payment date
Spirax-Sarco Engineering PLCdividend payment date
Travis Perkins PLCdividend payment date
Monday 13 November 
no events scheduled 
Tuesday 14 November 
no events scheduled 
Wednesday 15 November 
Coats Group PLCdividend payment date
Ferguson PLCdividend payment date
JP Morgan Mid Cap Investment Trust PLCdividend payment date
Strategic Equity Capital PLCdividend payment date
Thursday 16 November 
abrdn Property Income Trust Ltdex-dividend payment date
Asian Energy Impact Trust PLCex-dividend payment date
Baillie Gifford Japan Trust PLCex-dividend payment date
BlackRock Greater Europe Investment Trust PLCex-dividend payment date
Bunzl PLCex-dividend payment date
Bytes Technology Group PLCex-dividend payment date
Centrica PLCdividend payment date
Coca-Cola Europacific Partners PLCex-dividend payment date
DX Group PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
GCP Asset Backed Income Fund Ltdex-dividend payment date
GSK PLCex-dividend payment date
Hargreaves Lansdown PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
ICG Enterprise Trust PLCex-dividend payment date
James Halstead PLCex-dividend payment date
Lancashire Holdings Ltdspecial ex-dividend payment date
Majedie Investments PLCex-dividend payment date
Marks & Spencer Group PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
New Star Investment Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Personal Group Holdings PLCdividend payment date
Redrow PLCdividend payment date
Regional REIT Ltdex-dividend payment date
Schroder Oriental Income Fund Ltdex-dividend payment date
Scottish American Investment Co PLCex-dividend payment date
SCS Group PLCex-dividend payment date
Shell PLCex-dividend payment date
Supermarket Income REIT PLCdividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
Unilever PLCex-dividend payment date
Wincanton PLCex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
8 Nov 2023 09:30

LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
2 Nov 2023 10:14

LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.